Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segme…
| Periodo | 2026-10 | 2025-05 | 2025-01 | 2024-11 |
|---|---|---|---|---|
| Real | — | $19.11 | $16.94 | $15.83 |
| Estimado | — | $17.13 | $16.15 | $17.69 |
| Sorpresa | — | +11.6% | +4.9% | -10.5% |
| Métrica | RDY | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 58.5% | 57.4% | +1.1% |
| Operating Margin | 22.1% | -34.4% | +56.5% |
| Net Margin | 17.4% | -32.5% | +49.8% |
| FCF Margin | 5.8% | -12.6% | +18.4% |
| ROE | 17.0% | -39.2% | +56.1% |
| ROA | 11.5% | -30.9% | +42.4% |
| Current Ratio | 1.92 | 2.73 | -0.81 |
| Debt / Equity | 0.02 | 0.28 | -0.26 |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✓Rentabilidad sobre activos positiva | 11.5% | — |
| ✓Flujo de caja operativo positivo | ₹46.4B | ₹45.4B |
| ✗Rentabilidad sobre activos al alza | 11.5% | 14.4% |
| ✗Caja operativa/activos supera al ROA | 9.4% | ROA 11.5% |
| ✗Menos deuda a largo plazo | 1.6% | 1.5% |
| ✗Mejor liquidez (ratio corriente) | 1.92 | 2.58 |
| ✗Sin aumentar el nº de acciones | 834M | 834M |
| ✗Margen bruto al alza | 58.5% | 58.6% |
| ✗Rotación de activos al alza | 0.66 | 0.72 |
| Calidad del negocio | FY25 |
|---|---|
| ✗Margen FCF > 10 % | 5.8% |
| ✓ROCE > 10 % | 19.8% |
| ✓Ventas > 5 %/año (3 años) | 14.9% |
| ✓Deuda neta/EBITDA < 3x | Caja neta |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 16.9% |
Riesgo de quiebra (Altman Z 6.3): zona segura
DR REDDYS LABORATORIES LTD cotiza a 13.07 USD y tiene una capitalización bursátil de $10.9B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud